Hörl Walter H
Klinische Abteilung für Nephrologie und Dialyse, Medizinische Universitätsklinik III, Medizinische Universität Wien, Austria.
Wien Klin Wochenschr. 2009;121(1-2):15-32. doi: 10.1007/s00508-009-1145-3.
Contrast media induced nephropathy is a common complication, particularly in high risk patients, such as patients with chronic kidney disease (CKD) and diabetes. The majority of studies show an increased in-hospital mortality and an unfavourable long-term prognosis after manifestation of contrast media induced nephropathy. The course and the potential risk factors of this type of acute renal failure are known. Therefore, an effective prophylaxis should allow to prevent this complication. In low risk patients oral or intravenous volume expansion is probably sufficient combined with the withdrawal of non-steroidal anti-inflammatory drugs. In high risk patients additional prophylactic measures are needed but their efficacy is not clearly defined. Therefore, heterogeneous recommendations exist. Hydration reduces (afferent) renovasoconstriction, the tubuloglomerular feedback, the tubulotoxic effects of contrast media (via dilution) and the oxygen radical formation. The optimal composition, timing and amount of fluid which should be administered to the patients remain unclear. Most studies show that intravenous administration of volume is more effective than oral fluid intake. The majority of studies found a benefit of isotonic sodium bicarbonate in comparison to isotonic saline solutions, even if meta-analyses displayed only a positive trend for sodium bicarbionate due to the heterogeneity of the data. Controversies exist for N-acetylcysteine, vitamin C, fenoldopam, theophylline or statins. Due to low cost and low side effects, N-Acetylcysteine is widely used. Theophyllin (given intravenously 30 minutes before contrast media injection) is renoprotective, particularly in intensive care unit patients. Very important is the reduction of contrast media volume (if possible <30 ml for diagnostic procedures and <100 ml for interventions). Iso-osmolar and low-osmolar contrast media may have a comparable low risk for the induction of contrast media induced nephropathy. This risk is probably higher after intra-arterial as compared to intravenous administration of contrast media. Controversies exist with respect to the reduction of contrast media induced nephropathy and mortality by prophylactic hemodialysis or hemofiltration. A possible benefit of these procedures consists probably for patients with advanced chronic kidney disease (stage 5). With the further increase of investigations using contrast media, with the further increase in vascular interventions, in age and comorbidities of the patients one may suggest that the problem of contrast media induced nephropathy will further increase, despite all prophylactic procedures so far recommended.
造影剂肾病是一种常见的并发症,尤其在高危患者中,如慢性肾脏病(CKD)患者和糖尿病患者。大多数研究表明,造影剂肾病发生后,患者的院内死亡率会升高,长期预后也不佳。这种类型的急性肾衰竭的病程和潜在危险因素是已知的。因此,有效的预防措施应能预防这种并发症。在低危患者中,口服或静脉补液扩容可能就足够了,同时停用非甾体类抗炎药。在高危患者中,需要采取额外的预防措施,但其疗效尚未明确界定。因此,存在不同的建议。补液可减轻(入球小动脉)肾血管收缩、管球反馈、造影剂的肾小管毒性作用(通过稀释)以及氧自由基的形成。应给予患者的最佳液体成分、时机和量仍不明确。大多数研究表明,静脉补液比口服补液更有效。大多数研究发现,与等渗盐水溶液相比,等渗碳酸氢钠有好处,即使由于数据的异质性,荟萃分析仅显示碳酸氢钠有积极趋势。对于N-乙酰半胱氨酸、维生素C、非诺多泮、茶碱或他汀类药物存在争议。由于成本低且副作用小,N-乙酰半胱氨酸被广泛使用。茶碱(在注射造影剂前30分钟静脉注射)具有肾脏保护作用,尤其在重症监护病房患者中。非常重要的是减少造影剂用量(如果可能,诊断性检查<30 ml,介入性操作<100 ml)。等渗和低渗造影剂诱发造影剂肾病的风险可能相当低。与静脉注射造影剂相比,动脉内注射造影剂后这种风险可能更高。关于预防性血液透析或血液滤过能否降低造影剂肾病和死亡率存在争议。这些措施可能对晚期慢性肾脏病(5期)患者有益。随着使用造影剂的检查进一步增加,随着血管介入操作、患者年龄和合并症的进一步增加,尽管有目前推荐的所有预防措施,造影剂肾病问题可能会进一步加剧。